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PLINICAL RESEARCH Clinical Trial
linical Outcomes in Managed-Care
atients With Coronary Heart
isease Treated Aggressively in
ipid-Lowering Disease Management Clinics
he ALLIANCE Study
ichael J. Koren, MD, FACC,* Donald B. Hunninghake, MD, FACC,† on behalf of the
LLIANCE Investigators
acksonville, Florida; and Minneapolis, Minnesota
OBJECTIVES This study sought to determine if an aggressive, focused low-density lipoprotein cholesterol
(LDL-C)-lowering strategy was superior to usual care for coronary heart disease (CHD)
patients enrolled in health maintenance organization or Veterans Administration settings.
BACKGROUND Statin therapy benefits are well established. No prospective, randomized studies have tested
strategies to optimize these benefits in a “real-world” setting.
METHODS A total of 2,442 CHD patients with hyperlipidemia were randomized to either an aggressive
treatment arm using atorvastatin or usual care and followed for 51.5 months on average.
Atorvastatin-group patients were titrated to LDL-C goals of 80 mg/dl (2.1 mmol/l) or a
maximum atorvastatin dose of 80 mg/day. Usual-care patients received any treatment deemed
appropriate by their regular physicians. End point assessments were complete in 958
atorvastatin-group and 941 usual-care patients. Partial assessments occurred in 259 patients
in the atorvastatin group and 284 patients in the usual care group who did not complete four
years of study participation because of adverse events, withdrawn consent, or follow-up loss.
The primary efficacy parameter was time to first cardiovascular event.
RESULTS A total of 289 (23.7%) patients in the atorvastatin group compared with 333 (27.7%) patients
in the usual care group experienced a primary outcome (hazard ratio, 0.83; 95% confidence
interval 0.71 to 0.97, p  0.02). This reduction in morbidity was largely due to fewer
non-fatal myocardial infarctions (4.3% vs. 7.7%, p 0.0002). Levels of LDL-C were reduced
more (34.3% vs. 23.3%, p  0.0001) and National Cholesterol Education Program goals
(LDL-C 100 mg/dl) more likely met at end-of-study visits (72.4% vs. 40.0%) in patients
receiving atorvastatin compared with those receiving usual care.
CONCLUSIONS An aggressive, focused statin therapy management strategy outperformed usual care in health
maintenance organization and Veterans Administration clinic patients with CHD. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.053Coll Cardiol 2004;44:1772–9) © 2004 by the American College of Cardiology Foundation
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aecent epidemiological data suggest that the downward
lope of the 40-year trend in U.S. cardiovascular disease
ortality that began in the 1950s has flattened over the last
everal years (1,2). Ironically, this change in trend may be
ccurring during a period when clinical trials have defini-
ively demonstrated significant morbidity and mortality
eductions in both primary and secondary prevention pop-
lations with drugs such as statins (3–9) and angiotensin-
onverting enzyme inhibitors (10–12). This disparity raises
uestions about whether benefits demonstrated in con-
From the *Jacksonville Center for Clinical Research, Jacksonville, Florida; and the
University of Minnesota, Minneapolis, Minnesota. Parke-Davis and Pfizer Phar-
aceuticals funded the study. Drs. Koren and Hunninghake were clinical investiga-
ors in the trial who were consulted on study design, collected subject information,
ssisted in all aspects of data analysis, and drafted the manuscript. The sponsors
nitiated the study design and also participated in all aspects of logistical support
uring the trial, statistical and data analyses, and manuscript preparation. Pfizer
harmaceuticals reviewed the final manuscript and assisted with editing and revisions,
ut the authors retained final decisions on content.p
Manuscript received May 8, 2004; revised manuscript received July 9, 2004,
ccepted July 13, 2004.rolled treatment trials are being achieved in clinical practice
13).
Recommendations of the second and third reports of the
ational Cholesterol Educational Program Adult Treat-
ent Panel (NCEP ATP) (14,15) for low-density lipopro-
ein cholesterol (LDL-C) lowering have been endorsed by
ost clinicians. These guidelines have become a quality
enchmark for managed care organizations, Health Plan
mployer Data and Information Set measurements, and
eart disease risk factor disease management programs.
lthough these recommendations are widely accepted, we
re unaware of studies that have prospectively compared
ifferent treatment strategies for compliance with these
uidelines and consequent clinical outcomes.
The Aggressive Lipid-Lowering Initiation Abates New
ardiac Events (ALLIANCE) study is the first prospective,
andomized trial, to our knowledge, to evaluate outcomes
ttributable to different lipid treatment strategies in a
redefined coronary heart disease (CHD) patient group.
D
t
a
p
e
f
r
M
S
b
c
c
c
o
o
C
V
s
s
w
u
a
S

a
s
(
s
(
w
m
a
m
L
l
t
c
o
m
h
b
a
d
m
a
d
s
t
i
r
t
a
i
c
f
s
c
c
E
e
c
r
w
a
c
p
a
p
t
m
e
t
r
m
o
a
e
i
S
t
p
f
f
f
n
a
1
r
c
i
a
w
e
i
o
1773JACC Vol. 44, No. 9, 2004 Koren et al.
November 2, 2004:1772–9 The ALLIANCE Studyuring the trial, patients were randomized at study centers
o receive either an aggressive lipid-lowering regimen using
torvastatin or “usual care” as deemed appropriate by the
atient’s regular physicians. The study was designed and
xecuted as a “real-world” trial to determine if an aggressive,
ocused approach to hyperlipidemia would outperform cur-
ent physician practice in CHD patients.
ETHODS
tudy design. The design of the ALLIANCE study has
een described in detail previously (16). The study was
onducted at 16 centers throughout the U.S. These centers
ould be a staff model health maintenance organization, a
ommunity physician open-provider health maintenance
rganization, or a Veterans Affairs system. The study was
pen only to patients identified by diagnosis codes related to
HD from relevant managed health care organizations or
eterans Administration facilities databases. Letters were
ent to these patients inviting them to be screened for the
tudy at research centers. After screening, eligible patients
ere randomized to either the atorvastatin group or the
sual-care group by the central laboratory between July 1995
nd June 1998.
tudy population. Eligible subjects were men or women
18 years of age with known CHD defined as a history of
cute myocardial infarction (MI) (3 months before
creening), percutaneous transluminal coronary angioplasty
6 months before screening), coronary artery bypass graft
urgery (3 months before screening), or unstable angina
3 months before screening). Inclusion LDL-C levels
ere between 110 mg/dl (2.8 mmol/l) and 200 mg/dl (5.2
mol/l) for patients receiving lipid-lowering medication
nd between 130 mg/dl (3.4 mmol/l) and 250 mg/dl (6.5
mol/l) for patients receiving no lipid-regulating therapy.
ipid therapy was not removed for the patients’ baseline
aboratory measurements. Approximately two-thirds of pa-
ients were on lipid-regulating agents at baseline.
The patients in atorvastatin group received study medi-
ation and underwent visits at the research center where
nly hyperlipidemia was treated. Primary-care physicians
anaged other cardiovascular risk factors. These patients
ad their current lipid-lowering therapy discontinued after
aseline laboratory measurements and were started on
torvastatin at 10 mg/day. The atorvastatin dosage was
oubled every four weeks until an LDL-C level of 80
g/dl (2.1 mmol/l) or a maximum dose of 80 mg/day was
Abbreviations and Acronyms
ALLIANCE  Aggressive Lipid-Lowering Initiation
Abates New Cardiac Events study
CHD  coronary heart disease
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarctionchieved. Combination lipid therapy was not allowed. After mose titration was completed, subjects were followed every
ix months.
The patients in the usual care group were maintained on
he lipid-lowering program already prescribed. Adjustments
n lipid therapy were made entirely at the discretion of
egular physicians. Lipid-regulating therapy in patients in
he usual care group could include atorvastatin after its
pproval in 1997. The patients in the usual care group were
nvited back to the research centers every six months for
ollection of adverse-event data. In many cases, these
ollow-up evaluations were performed by telephone because
ubjects in the usual-care arm received no medication,
ounseling, or interim laboratory tests from lipid study
enters.
fficacy and safety evaluations. Primary cardiovascular
vents included cardiac death, non-fatal MI, resuscitated
ardiac arrest, cardiac revascularization, and unstable angina
equiring hospitalization. The primary efficacy end point
as the time from randomization to the first occurrence of
primary cardiovascular event. Secondary outcomes in-
luded non-cardiac death, peripheral revascularization, hos-
italization for congestive heart failure, and stroke.
Laboratory analyses for the patients in the atorvastatin group
t baseline, at interim visits, and at study completion were
erformed by Pacific Biometrics (Seattle, Washington). For
he patients in the usual care group, laboratory values were
easured by the central laboratory only at baseline and at the
nd of the study. All other laboratory testing for the patients in
he usual care group was directed by treating physicians.
The study was conducted in accordance with the Decla-
ation of Helsinki and approved by the local ethics com-
ittees or institutional review boards. An independent
utcomes committee of five cardiologists reviewed and
djudicated all study outcomes. Interim monitoring of study
vents and serious adverse events was performed by an
ndependent data safety monitoring committee.
tatistical analyses. A sample size of 900 patients in each
reatment group (1,800 patients total) was expected to
rovide 90% power to detect a 29% reduction in the
our-year cumulative primary cardiovascular event rate (20%
or usual care and 14.2% for atorvastatin therapy). Allowing
or a 25% overall reduction in sample size due to patients
ot completing the study for personal or medical reasons
nd managed health care organizations attrition, accrual of
,200 patients per group (2,400 patients total) were to be
andomized to receive either atorvastatin therapy or usual
are.
Intention-to-treat analysis was performed on all random-
zed patients (n  2,442). For the primary end point
nalysis, Kaplan-Meier survival curves for the two groups
ere compared using the log-rank statistic. In addition,
ach primary outcome was analyzed separately to determine
f differences in time to event were present. The primary
utcomes were also examined by a Cox proportional hazards
odel to assess treatment differences adjusted for center
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The ALLIANCE Study November 2, 2004:1772–9ffect and any additional factors that might affect survival.
econdary outcomes were examined in a similar manner.
ESULTS
f 3,451 patients screened at 16 centers, 2,442 were
andomized, with 1,217 assigned to the atorvastatin group
nd 1,225 to the usual care group (Fig. 1). Patients were
een in the research centers from July 6, 1995, to July 17,
002. Demographic and clinical characteristics of patients
andomized to the atorvastatin and usual care groups were
imilar at baseline (Table 1). The patients were followed for
median period of 54.3 months (mean 51.5 months,
tandard error  0.37).
A total of 958 patients in the atorvastatin group and 941
n the usual care group completed end point assessments.
hese numbers included patients who returned for the final
isit, those who died during the course of the trial, and those
ho reported an end point during the study but were either
ost to follow-up at last patient visit or discontinued from
he trial before study end. Partial end point assessments
igure 1. Patient disposition. *The majority of patients not randomized faile
eath (primary end point). ‡Excludes cardiac death. DC  discontinued.ccurred in 259 patients in the atorvastatin group and 284atients in the usual care group who did not complete the
tudy for various reasons. These reasons included discon-
inuations for adverse events and administrative issues such
s withdrawn consent, protocol violations, and subjects lost
o follow-up. Patient disposition by study arm is shown in
igure 1.
In the atorvastatin group, the median dose of atorvastatin
eceived by patients over the course of the study was 40.5
g/day; 545 patients (45%) received 80 mg/day.
erum lipid levels. The mean LDL-C levels at baseline
on pre-randomization lipid-lowering treatment) were 147
g/dl (3.8 mmol/l) in the atorvastatin group and 146 mg/dl
3.8 mmol/l) in the usual care group. At the end of the
tudy, LDL-C levels had decreased by 34.3% to 95 mg/dl
2.5 mmol/l) in the atorvastatin group and by 23.3% to 111
g/dl (2.9 mmol/l) in the usual care group (p  0.0001)
Table 2). At study completion, 72.4% of patients in the
ocused group had achieved their ATP III goal (LDL-C
100 mg/dl [2.6 mmol/l]) compared with 40.0% of those
eceiving usual care (p  0.001).
eet inclusion criteria requiring a history of heart disease. †Includes cardiacThe patients in the atorvastatin group also demonstrated
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November 2, 2004:1772–9 The ALLIANCE Studyignificantly greater reductions in total cholesterol than
hose in the usual care group (p  0.0001). Reductions in
riglycerides and increases in high-density lipoprotein cho-
esterol were moderate in both groups (Table 2).
ardiovascular outcomes. During the study, 289 patients
23.7%) receiving aggressive treatment with atorvastatin
xperienced a primary outcome, compared with 333 patients
27.7%) receiving usual care (p  0.026) (Table 3). The
vent curves for the atorvastatin and usual care groups began
o diverge at approximately one year and continued to
eparate until the end of the study (Fig. 2). The Cox
egression model indicated a 17.1% reduction in the risk of
primary cardiovascular outcome for the patients in the
torvastatin group compared with patients in the usual care
roup (hazard ratio  0.829; p  0.020). This benefit of
ocused treatment compared with usual care was due largely
o a significant reduction in non-fatal MI (4.3% vs. 7.7%; p
0.0002). For this cardiovascular event, the Kaplan-Meier
urvival curves for the atorvastatin and usual care groups
eparated within months and continued to diverge up to the
tudy’s end (Fig. 3). The Cox regression model indicated a
Table 1. Demographics and Clinical Character
Characteristic Atorv
Age (yrs)
Mean (SD)
Min–max
Gender, n (%)
Male
Female
Ethnic group, n (%)
White/Caucasian
Black
Asian
Other
Unknown
Weight, kg
Mean (SD)
CAD risk factors
Family history of CAD, n (%)
Current smoker, n (%)
Diabetes, n (%)
Systolic blood pressure
Mean (SD), mm Hg
Diastolic blood pressure
Mean (SD), mm Hg
LDL cholesterol
Mean (SD), mg/dl [mmol/l] 147.0
Medical history, n (%)
MI
PTCA
CABG
Unstable angina
Congestive heart failure
Stroke
Peripheral revascularization
Other
CABG  coronary artery bypass graft surgery; CAD  c
myocardial infarction; PTCA  percutaneous transluminal c7.4% non-fatal MI risk reduction for atorvastatin therapy (ersus usual care (hazard ratio  0.526; p  0.0002).
rends favoring the aggressively treated group that did not
each statistical significance were seen for all other compo-
ents of the primary composite end point (Fig. 4). The Cox
egression analysis did not show statistically significant
nteractions between treatment and center (p  0.17).
ubgroup analyses by gender, age, and race showed efficacy
esults consistent with the overall population. No significant
nteractions between treatment and gender, age, or race
ere observed.
afety. The occurrence of serious adverse events was sim-
lar in the atorvastatin (40%) and usual care groups (42%).
n both treatment arms, the most commonly reported
erious adverse events were chest pain, atrial fibrillation,
neumonia, cellulitis, and gastrointestinal hemorrhage. No
nexpected safety concerns were identified in the patients
ggressively treated with atorvastatin.
Protocol-stipulated routine laboratory testing, performed
nly in the atorvastatin group, showed abnormal aspartate
minotransferase or alanine aminotransferase levels (3
imes the upper limit of normal) in 8 (0.7%) and 16 patients
of Total Patient Population
n (n  1,217) Usual Care (n  1,225)
(9.0) 61.3 (8.6)
–78 34–78
(82.2) 1,008 (82.3)
(17.8) 217 (17.7)
(84.0) 1,026 (83.8)
(11.4) 139 (11.3)
(0.8) 8 (0.7)
(3.7) 52 (4.2)
(0.1) 0 (0.0)
(17.5) 88.5 (16.8)
(18.9) 256 (20.9)
(19.6) 237 (19.3)
(23.2) 258 (21.1)
(18.3) 134.7 (18.5)
(10.6) 78.7 (10.2)
) [3.8 (0.70)] 147.2 (26.4) [3.8 (0.70)]
(60.1) 680 (55.5)
(39.0) 477 (38.9)
(49.5) 608 (49.6)
(21.5) 252 (20.6)
(5.8) 91 (7.4)
(6.8) 79 (6.4)
(4.2) 42 (3.4)
(15.5) 175 (14.3)
ry artery disease; LDL  low-density lipoprotein; MI 
ry angioplasty; SD  standard deviation.istics
astati
61.1
31
1,000
217
1,022
139
10
45
1
88.9
230
238
282
134.2
78.9
(26.0
732
475
602
262
71
83
51
189
orona
orona1.3%), respectively. The mean changes in aspartate amino-
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The ALLIANCE Study November 2, 2004:1772–9ransferase (2.7 U/l) and alanine aminotransferase (3.1 U/l)
ere not clinically significant. There were no documented
ases of creatine phosphokinase levels 10 times upper
imit of normal in the atorvastatin group and no docu-
ented cases of rhabdomyolysis or myopathy in either
roup. There were 144 cases of cancer, with 67 in the
torvastatin group and 77 in the usual care group.
ISCUSSION
ultiple landmark studies over the past decade have estab-
ished statin therapy as a cornerstone of preventative car-
iovascular care. These placebo-controlled trials have dem-
nstrated the benefit of several agents in various primary
nd secondary prevention populations. The ALLIANCE
Table 2. Changes in Serum Lipid Levels
Variable
LDL cholesterol
n
Baseline mean (SE), mg/dl (mmol/l)
Last patient visit mean (SE), mg/dl (mmol/l)
LS mean % change (SE)
HDL cholesterol
n
Baseline mean (SE), mg/dl (mmol/l)
Last patient visit mean (SE), mg/dl (mmol/l)
LS mean % change (SE)
Total cholesterol
n
Baseline mean (SE), mg/dl (mmol/l)
Last patient visit mean mg/dl (mmol/l)
LS mean % change (SE)
Triglycerides
n
Baseline mean (SE), mg/dl (mmol/l)
Last patient visit mean (SE), mg/dl (mmol/l)
Median % change (range)§
LS mean % change (SE)
*p  0.0001, †p  0.01, ‡p  0.05 vs. usual care. §Median
Mean time elapsed between baseline and follow-up lipid valu
the usual-care group. LS mean and SE based on analysis of
value.
LDL  low-density lipoprotein; LS  least squares; HD
able 3. Number and Percentage of Primary and Secondary Outc
Atorvastatin
(n  1,217)
rimary outcome 289 (23.7)
Cardiac death 43 (3.5)
Nonfatal MI 52 (4.3)
Resuscitated cardiac arrest 2 (0.2)
Cardiac revascularization 197 (16.2)
Unstable angina requiring hospitalization 126 (10.4)
econdary outcome 211 (17.3)
All-cause mortality 121 (9.9)
Peripheral revascularization 50 (4.1)
Hospitalization for CHF 42 (3.5)
Stroke 35 (2.9)
ny outcome (primary or secondary) 408 (33.5)By Cox proportional hazards model with center as a covariate.
CHF  congestive heart failure; CI  confidence interval; other abbreviations as in Tatudy breaks ground by showing the incremental benefit
ttributable to an aggressive, focused clinical strategy com-
ared with usual care in predefined groups of CHD patients
ith equal access to health care resources.
Patients in both the atorvastatin and usual care groups
xperienced significant reductions in LDL-C levels from
aseline measurements obtained on pre-study lipid therapy.
bout two-thirds of patients in each group were on lipid-
owering medication at the time of baseline measurements.
onsidering the significant improvement of lipid levels from
aseline in patients in the usual care group, the incremental
linical benefit of the aggressively treated cohort in the ALLI-
NCE study is particularly impressive. The patients in the
torvastatin group had, on average, an additional 16 mg/dl
Atorvastatin Usual Care
1,146 725
47 (0.8) [3.8 (0.02)] 146 (0.9) [3.8 (0.02)]
95 (0.8) [2.5 (0.02)] 110 (0.8) [2.8 (0.03)]
34.3 (0.7)* 23.3 (0.9)
1,147 726
40 (0.3) [1.0 (0.01)] 41 (0.4) [1.1 (0.01)]
42 (0.3) [1.1 (0.01)] 43 (0.5) [1.1 (0.01)]
6.1 (0.7)† 8.5 (0.8)
1,147 725
26 (1.0) [5.8 (0.03)] 225 (1.2) [5.8 (0.03)]
70 (1.1) [4.4 (0.03)] 189 (1.4) [4.9 (0.04)]
24.1 (0.5)* 15.5 (0.7)
1,147 726
97 (3.2) [2.2 (0.04)] 198 (4.2) [2.2 (0.05)]
70 (4.0) [1.9 (0.05)] 183 (4.5) [2.1 (0.05)]
17.8 (92.7–656.5) 11.0 (84.9–344.1)
7.4 (1.8)‡ 2.4 (2.2)
e represented secondary to non-normal distribution of data.
54.7 months for the atorvastatin group and 54.0 months for
ance model with factors for treatment, center, and baseline
high-density lipoprotein; SE  standard error.
Events
Usual Care
(n  1,225) Hazard Ratio* (95% CI) p Value*
333 (27.2) 0.83 (0.71–0.97) 0.020
61 (5.0) 0.69 (0.47–1.02) 0.059
94 (7.7) 0.52 (0.38–0.74) 0.0002
5 (0.4) 0.37 (0.07–1.89) 0.229
225 (18.4) 0.84 (0.70–1.02) 0.080
147 (12.0) 0.83 (0.65–1.05) 0.125
225 (18.4) 0.91 (0.75–1.09) 0.303
127 (10.4) 0.92 (0.72–1.18) 0.523
58 (4.7) 0.84 (0.57–1.22) 0.360
56 (4.6) 0.73 (0.49–1.09) 0.119
39 (3.2) 0.87 (0.55–1.38) 0.552
443 (36.2) 0.88 (0.77–1.01) 0.0601
2
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November 2, 2004:1772–9 The ALLIANCE Studyeduction in LDL-C beyond that of patients in the usual care
roup at end-of-study visits and experienced a 17% overall and
7% non-fatal MI risk reduction.
The absolute risk reduction attributable to aggressive
ipid therapy compared to usual care was 4% or 1 patient
pared from a primary end point for each 25 patients
reated. If this incremental benefit is added to the expected
isk reduction accrued by patients in the usual care group
ecause of improvements in their lipid levels during the
tudy, the overall benefit of aggressive treatment is even
reater. Further, the health benefits of aggressive lipid
reatment were particularly favorable in that they were
eighted toward reduction of “hard” end points such as
on-fatal MIs and cardiac death (Fig. 4).
Figure 2. Kaplan-Meier estimatFigure 3. Kaplan-Meier estimates for time toAlthough not defined a priori as a study end point, the
ate of non-fatal MI and cardiac death combined was
educed by 42.6% in the atorvastatin group compared with
he usual care group (hazard ratio  0.574, 95% confidence
nterval 0.442 to 0.746; p  0.0001).
The ALLIANCE study adds important safety informa-
ion about the use of high-dose statin therapy. It is
eassuring that patients treated aggressively achieved their
oals with a low risk of adverse drug effects. Nearly one-half
f the patients in the atorvastatin group received the
aximum 80-mg dose, and the incremental clinical benefits
bserved in the atorvastatin group compared with the usual
are group occurred without any detectable safety differ-
nces. The long-term ALLIANCE study also supports
time to first primary outcome.non-fatal myocardial infarction (MI).
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The ALLIANCE Study November 2, 2004:1772–9tudies of shorter duration (17–19) showing that high-dose
torvastatin is well tolerated.
tudy limitations. The design of the ALLIANCE study
s a “real-world” study was both a strength and weakness.
tudy center follow-up of patients was limited to every six
onths once the initial dose titration of patients in the
torvastatin group was completed. This infrequent
ollow-up at study centers was designed to minimize the
isruption of standard care and to limit crossover of patients
n the usual care group to the atorvastatin group treatment
atterns. In the initial study design, we envisioned that
harmacy, laboratory, and health care resource utilization
ata would be obtained from managed-care databases.
Unfortunately, due to the vicissitudes of the health care
arketplace, managed-care databases for most subjects
ould not be accessed as anticipated. This limitation oc-
urred because of the financial failure or merger of most of
he managed-care organizations during the study. We also
ound that patients treated in one managed care often
witched to another and that most hospitalizations and
uch other health care resource utilization occurred outside
f systems controlled by managed-care entities. Because of
hese shortcomings, we do not have data on medication use
r interim laboratory values of patients in the usual care
roup. Additionally, we have fewer verifiable follow-up lipid
alues in patients in the usual care group compared with the
torvastatin group (725 vs. 1,146) because patients in the
sual care group received interim lipid profiles at the
iscretion of their treating physicians. The patients in the
sual care group who discontinued study participation early
ecause of events or dropouts often did not have follow-up
ipids drawn at study sites.
Lack of access to managed-care data also limited our efforts
o tally the reasons for patient study dropout. For example, we
etermined that 68 patients in the atorvastatin group stopped
tudy participation because of non-serious side effects. The
atients in the usual care groups who dropped out could not be
Figure 4. Effect of atorvastatin and usual careimilarly classified because of insufficient details on drug Aolerance in this group. Therefore, the patients in the usual care
roup who dropped out were classified as unwilling to continue
r lost to follow-up, although we believe that some unknown
umber of these patients discontinued study participation
ecause of statin intolerance. Fortunately, due to the persis-
ence of study sites, we obtained records for all patients known
o have been hospitalized. This effort allowed us to calculate a
erious adverse event rate for each study group and to conclude
hat there were no serious cases of rhabdomyolysis in either
roup.
Privacy issues also contributed to difficulties that would not
ave occurred had the study been performed entirely in a
esearch setting. Because they were recruited in the ALLI-
NCE study through managed-care databases rather than
hrough relationships with physician investigators, patients
ay have been less willing to share follow-up information after
hanging health plans and may have subsequently withdrawn
onsent at a higher rate in the ALLIANCE study compared
ith more traditional clinical trials. Additionally, several inves-
igators cited privacy issues when asked if they would expand
heir efforts to retrieve information from patients who had
hanged health plans, clinical providers, or their residence. The
oss to follow-up rate among Veterans Administration study
ubjects was lower than that for health maintenance organiza-
ion participants (6.3% vs. 9.8%), suggesting that future studies
uch as the ALLIANCE study may be most successful in
ingle-payer health care environments.
To mitigate this issue of incomplete follow-up, we per-
ormed analyses on both the cohort for which we had complete
nformation and the cohort whose survival status was known
rom death index data and partial records. There were no
ignificant differences between these groups. We believe that
he higher-than-expected dropout rate is unlikely to have a
aterial impact on the efficacy results of the trial, because
osing patients to follow up was mostly related to nonmedical
ssues (changing health plans and privacy concerns).
Future lipid guidelines may consider the results of the
imary outcomes. MI  myocardial infarction.LLIANCE study and other recent trials such as the
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REVERSAL) (19) and Pravastatin or Atorvastatin Evalu-
tion and Infection Therapy (PROVE-IT) (20) that have
emonstrated the benefit of lipid-lowering below current
uidelines in high-risk patients. Some of the pitfalls of
reating CHD patients in the “real world” should also be
onsidered. For example, in the ALLIANCE study, the
torvastatin group mean LDL-C of 95 mg/dl at study
ompletion was above a target of 80 mg/dl (2.1 mmol/l).
he mean end study LDL-C of 111 mg/dl in the usual care
roup fell short of the NCEP goal of 100 mg/dl. In light of
hese results, perhaps the treatment paradigm for cholesterol
anagement should shift from a target LDL-C goal to a
aximum acceptable level for a given patient risk type.
uture guidelines may also recommend expanded use of the
ocused disease management techniques that helped pa-
ients in the atorvastatin group meet current NCEP goals
early twice as often as patients in the usual care group.
ocused disease management may achieve results through
etter compliance with aggressive pharmacological therapy,
upport for non-pharmacological dietary measures, and
ncouragement of lifestyle changes such as increased phys-
cal activity.
onclusions. In summary, an aggressive, focused approach
o LDL-C lowering using atorvastatin improved clinical
utcomes compared with usual care for patients with CHD.
his incremental benefit was accomplished without addi-
ional risk. The ALLIANCE study results further support a
rowing body of evidence to suggest that LDL-C treatment
oals below current guidelines are desirable for appropriate
atients (7–9,17–21).
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